Zymeworks R&D spend
Zymeworks Inc. · ZYME (NASDAQ) · Vancouver, BC · Pharmaceuticals
Latest R&D (CAD)
$191.5M
Period ended 2025-12-31
Revenue (CAD)
$148.1M
129.3% of revenue · scale $168.4M
R&D by fiscal period
2025
$191.5M
2024
$184.4M
2023
$193.8M
2022
$271.4M
2021
$250.4M
2020
$229.7M
| Period end | R&D (CAD) | Revenue (CAD) | Native R&D | Form | Source |
|---|---|---|---|---|---|
| 2025-12-31 | $191,498,600 | $148,117,877 | $137,000,000 USD | 10-K | SEC EDGAR |
| 2024-12-31 | $184,403,846 | $104,521,219 | $134,621,000 USD | 10-K | SEC EDGAR |
| 2023-12-31 | $193,842,564 | $102,593,396 | $143,619,000 USD | 10-K | SEC EDGAR |
| 2022-12-31 | $271,445,975 | $536,762,827 | $208,596,000 USD | 10-K | SEC EDGAR |
| 2021-12-31 | $250,389,132 | $33,443,380 | $199,752,000 USD | 10-K | SEC EDGAR |
| 2020-12-31 | $229,668,825 | $52,252,767 | $171,203,000 USD | 10-K | SEC EDGAR |